Zoetis (NYSE:ZTS) Coverage Dropped by Analysts at BTIG Research

BTIG Research dropped coverage on shares of Zoetis (NYSE:ZTS) in a research note published on Friday,Benzinga reports. The firm had previously set a “buy” rating on the stock.

Several other equities analysts have also recently commented on the stock. Stifel Nicolaus reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. Jefferies Financial Group cut shares of Zoetis from a “buy” rating to a “hold” rating and lowered their target price for the stock from $103.00 to $83.00 in a research note on Tuesday, October 20th. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. Piper Sandler reduced their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Finally, The Goldman Sachs Group assumed coverage on shares of Zoetis in a research report on Friday, October 16th. They set a “neutral” rating and a $74.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $93.79.

Zoetis Stock Up 1.1%

Shares of NYSE ZTS opened at $79.67 on Friday. Zoetis has a 52 week low of $68.77 and a 52 week high of $144.83. The business has a 50-day simple moving average of $75.04 and a two-hundred day simple moving average of $93.64. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a market cap of $32.92 billion, a P/E ratio of 11.98, a P/E/G ratio of 1.17 and a beta of 0.74.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the firm earned $1.76 EPS. The company’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts anticipate that Zoetis will post 6.15 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is 34.93%.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ascent Group LLC increased its holdings in shares of Zoetis by 31.7% in the third quarter. Ascent Group LLC now owns 14,310 shares of the company’s stock worth $999,000 after buying an additional 3,444 shares during the period. Kelleher Financial Advisors lifted its stake in shares of Zoetis by 239.2% in the 3rd quarter. Kelleher Financial Advisors now owns 563 shares of the company’s stock valued at $39,000 after acquiring an additional 397 shares during the last quarter. Markel Group Inc. boosted its holdings in Zoetis by 542.5% during the 3rd quarter. Markel Group Inc. now owns 425,296 shares of the company’s stock valued at $29,698,000 after acquiring an additional 359,101 shares during the period. Parr Mcknight Wealth Management Group LLC boosted its holdings in Zoetis by 9.2% during the 3rd quarter. Parr Mcknight Wealth Management Group LLC now owns 21,501 shares of the company’s stock valued at $1,501,000 after acquiring an additional 1,811 shares during the period. Finally, Provenance Wealth Advisors LLC boosted its holdings in Zoetis by 1,866.7% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 531 shares of the company’s stock valued at $37,000 after acquiring an additional 504 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.